Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
about
Risk-benefit assessment of ivabradine in the treatment of chronic heart failureEffects of maximal sodium and potassium conductance on the stability of Hodgkin-Huxley model.Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series.Effect of Ivabradine on Heart Rate and Duration of Exercise in Patients With Mild-to-Moderate Mitral Stenosis: A Randomized Comparison With MetoprololThe Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome PatientsIvabradine (Corlanor) for Heart Failure: The First Selective and Specific I f Inhibitor.Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.Hyperpolarization activated cation current (I(f)) in cardiac myocytes from pulmonary vein sleeves in the canine with atrial fibrillation.Chronic Treatment with Ivabradine Does Not Affect Cardiovascular Autonomic Control in Rats.Postural orthostatic tachycardia syndrome (POTS).Cyclic nucleotide-regulated cation channels.Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure.Ivabradine: Current and Future Treatment of Heart Failure.Ivabradine in Management of Heart Failure: a Critical Appraisal.Ivabradine: Heart Failure and Beyond.New Targets in the Drug Treatment of Heart Failure.Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytesIvabradine in sepsis.Capsazepine concentration dependently inhibits currents in HEK 293 cells mediated by human hyperpolarization-activated cyclic nucleotide-gated 2 and 4 channels.Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy.If Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies.Clinical Course and Treatment of Dilated Cardiomyopathy During Twenty Years of Follow-up.Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo.Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction.Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat.Dose-dependent protective effect of ivabradine against ischemia-reperfusion-induced renal injury in rats.Effects of Ivabradine on Left Ventricular Systolic Function and Cardiac Fibrosis in Rat Myocardial Ischemia-Reperfusion ModelIvabradine Versus Beta-Blockers in Mitral Stenosis in Sinus Rhythm: An Updated Meta-Analysis of Randomized Controlled Trials
P2860
Q33568592-2D784098-006C-4FD3-98DE-51F07E980454Q33930260-E9B35731-0968-41C3-86C4-BD876A1EFE31Q33937346-09E492B4-FFC5-44B8-BC60-3F535C692A5CQ35705377-99360321-EE17-4D34-B759-EC7DFC50C8C1Q35914816-90C72E2B-6775-48E4-978B-D7C5B0F9BFC5Q36351531-BECD3FDB-25F6-4DAF-8D1F-292327BC390BQ36398719-BF03A98C-89B3-4523-8403-3712F5BFCE16Q36533529-66D2A705-66E8-4B2B-9380-BE01541024A6Q37126021-DDA677AF-E1A1-4C23-AB0B-1CC2E02F4E21Q37224055-B379DE2C-E3ED-4A86-9FDB-A3A5E1EC79A5Q37340786-5889D990-402F-4F4E-889F-3380C045B851Q38235948-8BD21711-0176-464A-BBC1-110459EDE977Q38546075-461741E7-3C4D-49F0-9C9B-955D89F2DEC9Q38546740-5DDA4D07-7FB7-4864-9CB2-2766488C2EF7Q38546764-594E8D01-D085-4F27-B051-21EC4AE1A76FQ38667210-D0BACCE6-37C9-4217-B43C-AA9056F21B4BQ38697074-0E1A1304-6686-4F72-BCD2-EC35512DDC79Q40333918-D54872EF-901B-4C60-BC67-D8FD41F667FFQ41984391-11EA1057-7836-4E50-A35B-68F25138E123Q45386818-626229B2-9CB8-479B-9B21-E06406E426EEQ46027547-1340A1E6-34AB-4F9F-98EA-4BACE28C3024Q47114756-2DFFE840-31C9-49E1-AE3A-04AA5A48B7D3Q49447986-2FCF1433-375B-412D-8EE7-99D19017D07EQ50765143-91E9D931-AC96-4B9F-8EC9-0C66DD07A90DQ50856225-9CE79DCE-16CF-42F1-8DC7-AAA19E2B4FB4Q51358496-A04B0F51-8795-4616-B266-E7615A1C4CB9Q54453543-42E846CA-93DB-4294-8A5E-8D4D3CA4EF47Q57120838-B756F84F-4CA1-4151-8408-E6E0F3C019E3Q58790420-D3E1742D-875A-4139-8E59-991FD1CD5F1A
P2860
Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Ivabradine -- the first select ...... the treatment of stable angina
@nl
Ivabradine -- the first select ...... he treatment of stable angina.
@ast
Ivabradine -- the first select ...... he treatment of stable angina.
@en
type
label
Ivabradine -- the first select ...... the treatment of stable angina
@nl
Ivabradine -- the first select ...... he treatment of stable angina.
@ast
Ivabradine -- the first select ...... he treatment of stable angina.
@en
prefLabel
Ivabradine -- the first select ...... the treatment of stable angina
@nl
Ivabradine -- the first select ...... he treatment of stable angina.
@ast
Ivabradine -- the first select ...... he treatment of stable angina.
@en
P2860
P3181
P1476
Ivabradine -- the first select ...... he treatment of stable angina.
@en
P2093
P2860
P304
P3181
P356
10.1111/J.1742-1241.2006.00817.X
P407
P577
2006-02-01T00:00:00Z